Search results for: Market Access
Filter search results
The Value of Vaccines and Taskforces
7 February 2023, 3:00pm
…England Ruth Todd, Chief Commercial Officer – HS2, and Former Programme Director of Vaccines Taskforce Stuart Carroll, Director of Market Access & Policy – Moderna, and Visiting Fellow – OHE…
Grow and diversify funding for prevention to boost the nation’s health and prosperity, urges landmark report
12 October 2023
…lack of uptake, underfunding, and short-termism Highly cost-effective NHS diabetes prevention programme with an estimated 13.6 million eligible, only accessible to 200,000 a year New financing models, such as social…
Biosimilar Competition: Lessons from Europe and Prospects for the US
14 March 2014, 12:00am
…European countries on Eprex® (epoetin alpha) and Neupogen® (filigrastim) and their biosimilars. He also discussed experience with two biosimilar-like products in the US and identified barriers to market penetration by biosimilars….
PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing
5 October 2015, 11:00pm
…fair and objective assessment of their value, and competitive market forces should encourage price competition. In practice, of course, these remain highly challenging goals. This lunchtime seminar will debate whether…
OHE Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
14 June 2017, 11:00pm
…protected the UK from seeing all-cause mortality rates rise. Preliminary but plausible story of cumulative disadvantage over life, in the labour market, in marriage and child outcomes, and in health;…
OHE Lunchtime Seminar: Management in the NHS
4 September 2017, 11:00pm
…markets. Professor Propper is also a research fellow of CEPR, Europe’s network of leading economists, a Research Fellow of the Institute of Fiscal Studies, and has served on the ESRC…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
5 June 2019, 11:00pm
…returns. A dynamic approach is therefore required to allow for the arrival of a new breakthrough product to the market in the first period; a second period in which potentially…
OHE Lunchtime Seminar: Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level
13 October 2019, 11:00pm
…time of the NHS internal market reforms in the early 1990s. They devised a receptive context for change framework, including the five factors we have used for our project. Some…
Lunchtime Seminar: US Pharma Pricing
7 April 2010
…us at OHE for a lunchtime seminar. The discussion will focus on the available evidence on the relationships between market prices and therapeutic value in the US, with comparisons to…